U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H28N2O5.ClH
Molecular Weight 460.95
Optical Activity ( - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENAZEPRIL HYDROCHLORIDE

SMILES

Cl.CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(CC(O)=O)C2=O

InChI

InChIKey=VPSRQEHTHIMDQM-FKLPMGAJSA-N
InChI=1S/C24H28N2O5.ClH/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28;/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28);1H/t19-,20-;/m0./s1

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C24H28N2O5
Molecular Weight 424.4895
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/pro/benazepril.html | DOI: 10.1111/j.1527-3466.1990.tb00432.x

BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and also in preventing the renal and retinal complications of diabetes. BENAZEPRIL, (±)- is used as USP Reference Standard.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Benazepril crossed the blood-brain barrier only to an extremely low extent.

Originator

Approval Year

1991
122
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 14.0 nM [IC50]
Inhibitor
8504
 0.1 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
LOTENSIN

Approved Use

Amlodipine besylate and benazepril hydrochloride capsules is a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent (1) 1.1 Hypertension Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.

Launch Date

1991
Primary
Approved
8583
BENAZEPRIL HYDROCHLORIDE

Approved Use

Benazepril hydrochloride tablets are indicated for the treatment of hypertension. They may be used alone or in combination with thiazide diuretics.

Launch Date

1991
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
437 pmol/g
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2344861
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
334 pmol × h/g
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2344861
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.6 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2344861
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Other AEs: Headache, Back pain...
Other AEs:
Headache (8.6%)
Back pain (2.6%)
Diarrhoea (0.9%)
Upper respiratory tract infection (3.4%)
Peripheral oedema (1.7%)
Sinusitis (1.7%)
Fatigue (0.9%)
Cough (1.7%)
Arthralgia (0.9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Fatigue...
Other AEs:
Headache (9%)
Fatigue (2%)
Nausea (2%)
Dizziness (2%)
Cough increased (2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (3%)
Dizziness postural (1%)
Cough increased (2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (2%)
Dizziness postural (1%)
Cough increased (1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Dizziness...
Other AEs:
Headache (6%)
Dizziness (2%)
Dizziness postural (2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Fatigue...
Other AEs:
Headache (2%)
Fatigue (5%)
Nausea (1%)
Cough increased (1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
AEs

AEs

AESignificanceDosePopulation
Arthralgia 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Diarrhoea 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Fatigue 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Cough 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Peripheral oedema 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Sinusitis 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Back pain 2.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Upper respiratory tract infection 3.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Headache 8.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Cough increased 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Fatigue 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Nausea 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness postural 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Nausea 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Cough increased 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Fatigue 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Cough increased 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness postural 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Nausea 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Fatigue 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 3%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness postural 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 6%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Cough increased 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Nausea 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 2%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Fatigue 5%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OATP1B1
1079
PEPT1
60

CES1
45
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OATP1B1
1095
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES1
45
 yes
PEPT1
60
 yes
PubMed

PubMed

TitleDatePubMed
Sympathomoderating influence of benazepril in essential hypertension.
1992 Apr
Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension.
1992 Jul-Aug
[Serological study on inhibitory function of shenkang injection on glomerular mesangial cell].
2001 Jul
[CEA comprehensive evaluation for Western and traditional Chinese hypotensive drugs].
2001 Sep
[Effects of benazepril on apoptosis in the kidney of diabetic rats].
2002 Jun
[Clinical observation on effect of shenle capsule in treating mesangial proliferating glomerulonephritis].
2002 May
[Non-immunologic factor: immunosuppressive drug-induced nephrotoxicity].
2002 Nov
The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats.
2002 Nov
Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
2002 Nov
Optimisation by experimental design of a capillary electrophoretic method for the separation of several inhibitors of angiotensin-converting enzyme using alkylsulphonates.
2002 Nov 29
Reoptimization of MDL keys for use in drug discovery.
2002 Nov-Dec
Effects of antihypertensive drugs on peritoneal vessels in hypertensive dogs with mild renal insufficiency.
2003
ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.
2003
[The use of angiotensin-converting enzyme inhibitor benazepril in acute period of myocardial infarction].
2003
[Comparative effectiveness of lotensin and capoten in patients with chronic cardiac failure].
2003
Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
2003 Apr
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
2003 Apr
Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril.
2003 Aug
Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
2003 Aug
Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure.
2003 Dec
[Effect of the compound of traditional Chinese drugs on gene expression of renal endothelin and its receptor of experimental diabetic nephropathy].
2003 Feb
Linear IgA dermatosis induced by a new angiotensin-converting enzyme inhibitor.
2003 Feb
Quantitative determination of benazepril and benazeprilat in human plasma by gas chromatography-mass spectrometry using automated 96-well disk plate solid-phase extraction for sample preparation.
2003 Jan 5
Argyria associated with colloidal silver supplementation.
2003 Jul
The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH).
2003 Jul-Aug
Rationale for combination therapy as initial treatment for hypertension.
2003 Jul-Aug
Using the electronic medical record to enhance the use of combination drugs.
2003 Jul-Aug
An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.
2003 Jun
Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting.
2003 Jun
[Study on candidate genes of benazepril related cough in Chinese hypertensives].
2003 Jun
Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
2003 Jun
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
2003 Mar
Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor.
2003 Mar
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
2003 Mar
Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
2003 Mar
[Postmarketing surveillance of benazepril-related cough and related risk factors analysis on hypertensives].
2003 May
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
2003 May-Jun
Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients.
2003 Nov
Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy.
2003 Nov-Dec
By the way, doctor. After a recent blood pressure check, my doctor bumped up my dose of Lotensin [an ACE inhibitor] from 10 milligrams to 20. I had been taking the 10-mg pill in the morning, but my doctor advised me to take the new, higher dose in the evening. He said most strokes and heart attacks happen in the morning, and that I could get better protection by taking the drug right before. But I read in the Health Letter a couple of months ago that you recommend morning intake, so I am confused.
2003 Oct
[Vasopressin analogue injection as ultimate measure for counteracting severe catecholamine-refractory poisoning by several vasodilators taken with suicidal intent].
2003 Oct 17
Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
2003 Oct 4
Angiotensin II inhibition increases cellular glucose transport during reperfusion but not ischemia in pig hearts.
2003 Sep
Systemic contact dermatitis due to captopril without cross-sensitivity to fosinopril, quinapril and benazepril.
2004
Effects of co-administration of urokinase and benazepril on severe IgA nephropathy.
2004 Apr
Hypertensive patients from two rural Chinese counties respond differently to benazepril: the Anhui Hypertension Health Care Study.
2004 Feb
Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
2004 Feb
Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis.
2004 Feb
Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass.
2004 Jan
Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus.
2004 Jan 13
Patents

Patents

08173840
4
08617587
4
JP2002322064A
4
JP2002535367A
25
JP2002536332A
39
JP2002538172A
23
JP2002541106A
100
JP2002541233A
406
JP2003503381A
36
JP2003508349A
46
JP2003515526A
470
JP2005041875A
13
JP2005526756A
4
JP2005527462A
22
JP2007520453A
36
JP2007524644A
51
JP2009102441A
4
JP2009526755A
475
JP2010043111A
14
JP2011506455A
52
JP2011510067A
60
JP2011510954A
147
JP2011524416A
146
JP4606172B2
29
JP4705912B2
48
JP4722295B2
105
JPH02121922A
14
JPH107566A
5
US4410520
4
WO2006084761A1
4

Sample Use Guides

In Vivo Use Guide
The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. The usual maintenance dosage range is 20-40 mg per day administered as a single dose or in two equally divided doses. A dose of 80 mg gives an increased response, but experience with this dose is limited.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In the isolated rabbit aorta the vasocontraction induced by PGF2 alpha was competitively antagonized at 10(-5)-10(-4) mol/l, while vascular responses induced by PGE1, PGE2 or PGI2 was inhibited at 3 x 10(-4) mol/l of benazepril. https://www.ncbi.nlm.nih.gov/pubmed/2080946
Benazepril inhibited both adrenaline-stimulated aortic PGI2 synthesis (25 pg mg -1 min-1) and carbachol-stimulated urinary bladder PGI2 synthesis (20 pg mg -1 min-1) in dose-dependent manners. IC50 (concentrations of antagonist at which agonist-stimulated PGI2 synthesis was inhibited by 50%) was 8 x 10-5.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:25:08 GMT 2025
Edited
by admin
on Mon Mar 31 18:25:08 GMT 2025
Record UNII
N1SN99T69T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENAZEPRIL HYDROCHLORIDE
EP   HSDB   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
LOTENSIN HCT COMPONENT BENAZEPRIL HYDROCHLORIDE
Preferred Name English
BENAZEPRIL HYDROCHLORIDE [EMA EPAR VETERINARY]
Common Name English
BENAZEPRIL HYDROCHLORIDE [JAN]
Common Name English
1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, monohydrochloride, [S-(R*,R*)]-
Common Name English
BENAZEPRIL HCL
Common Name English
BENAZEPRIL HYDROCHLORIDE COMPONENT CARDALIS
Common Name English
CGS-14824A HCL
Code English
BENAZEPRIL HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
NSC-758920
Code English
1H-1-Benzazepine-1-acetic acid, 3-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, hydrochloride (1:1), (3S)-
Systematic Name English
1H-1-Benzazepine-1-acetic acid, 3-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, monohydrochloride, (3S)-
Systematic Name English
(3S)-3-[[(1S)-1-Carboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid, 3-ethyl ester, monohydrochloride
Common Name English
BENAZEPRIL HYDROCHLORIDE [USAN]
Common Name English
Benazepril hydrochloride [WHO-DD]
Common Name English
BENAZEPRIL HYDROCHLORIDE [USP IMPURITY]
Common Name English
CARDALIS COMPONENT BENAZEPRIL HYDROCHLORIDE
Brand Name English
BENAZEPRIL HYDROCHLORIDE [HSDB]
Common Name English
FORTEKOR PLUS COMPONENT BENAZEPRIL HYDROCHLORIDE
Brand Name English
LOTENSIN
Brand Name English
BENAZEPRIL HYDROCHLORIDE [MI]
Common Name English
LOTREL COMPONENT BENAZEPRIL HYDROCHLORIDE
Common Name English
BENAZEPRIL HYDROCHLORIDE [ORANGE BOOK]
Common Name English
BENAZEPRIL HYDROCHLORIDE [EP IMPURITY]
Common Name English
BENAZEPRIL HYDROCHLORIDE [MART.]
Common Name English
BENAZEPRIL HYDROCHLORIDE [USP-RS]
Common Name English
Classification Tree Code System Code
EMA VETERINARY ASSESSMENT REPORTS FORTEKOR PLUS (AUTHORISED)
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
NCI_THESAURUS C247
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
EMA VETERINARY ASSESSMENT REPORTS CARDALIS (AUTHORIZED)
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
Code System Code Type Description
HSDB
86541-74-4
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
EVMPD
SUB13003MIG
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
ChEMBL
CHEMBL838
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
NSC
758920
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
DAILYMED
N1SN99T69T
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
SMS_ID
100000089958
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
MERCK INDEX
m2303
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY Merck Index
CAS
86541-74-4
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
RXCUI
235758
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY RxNorm
RS_ITEM_NUM
1048619
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
EPA CompTox
DTXSID9045922
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
FDA UNII
N1SN99T69T
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
USAN
Y-74
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
DRUG BANK
DBSALT000554
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
PUBCHEM
5362123
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
CHEBI
3012
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
NCI_THESAURUS
C28862
Created by admin on Mon Mar 31 18:25:08 GMT 2025 , Edited by admin on Mon Mar 31 18:25:08 GMT 2025
PRIMARY
Related Record Type Details
Structure of BENAZEPRIL HYDROCHLORIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Structure of BENAZEPRIL
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of (1S,3R)-Benazepril
IMPURITY -> PARENT
Impurity B: not more than 2.5 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.5 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 1,1-DIMETHYLETHYL ((3S)-3-AMINO-2-OXO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-1-YL)ACETATE
IMPURITY -> PARENT
Impurity F: not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.2 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of (3S)-3-Amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid
IMPURITY -> PARENT
Impurity E: not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.2 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENAZEPRIL, (R,R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENAZEPRILAT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of BENAZEPRILAT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENAZEPRIL HYDROCHLORIDE, (R,R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 1,1-DIMETHYLETHYL ((3S)-3-AMINO-2-OXO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-1-YL)ACETATE
IMPURITY -> PARENT
For the calculation of content, multiply the peak area by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENAZEPRIL, (R,R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENAZEPRIL ETHYL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of [(3S)-3-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino]-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid
IMPURITY -> PARENT
Impurity D: not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.2 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENAZEPRIL ETHYL ESTER
IMPURITY -> PARENT
Impurity G: not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.2 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 1,1-DIMETHYLETHYL ((3S)-3-AMINO-2-OXO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-1-YL)ACETATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of BENAZEPRIL
IMPURITY -> PARENT
Impurity C: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.3 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENAZEPRIL ETHYL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of [(3S)-3-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino]-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid
IMPURITY -> PARENT
)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of (3S)-3-Amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid
IMPURITY -> PARENT
For the calculation of content, multiply the peak area by 0.5.
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-nitroso-benazepril
IMPURITY -> PARENT
Structure of (3S)-3-Amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 3-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-Benzazepine-1-acetic acid hydrochloride
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of BENAZEPRILAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966